Today's brief highlights the expanding clinical footprint of personalized neoantigen vaccines across solid tumors and hematologic malignancies, with new trials launching in pancreatic, breast, and prostate cancers.
Concurrently, methodological advances in AI-driven epitope prediction and standardized bioinformatics workflows are addressing the computational bottlenecks of vaccine design.
Anda Biopharmaceutical has opened an expanded access program for PCNAT-01, a personalized tumor neoantigen peptide vaccine, for patients with resected pancreatic ductal adenocarcinoma. The program targets disease-free patients post-surgery and adjuvant therapy to reduce recurrence risk, subject to regulatory and sponsor review.
Dana-Farber Cancer Institute is recruiting for a Phase I trial of a personalized neoantigen vaccine in treatment-naïve, asymptomatic patients with IGHV-unmutated chronic lymphocytic leukemia (CLL). The regimen combines the vaccine with Poly-ICLC, cyclophosphamide, and pembrolizumab.
NEC Bio B.V. is recruiting for a Phase I/II trial of NECVAX-NEO1, a personalized neoantigen-targeting vaccine, in neoadjuvant triple-negative breast cancer. The study evaluates the vaccine in combination with standard-of-care anti-PD-1 therapy and chemotherapy, with potential post-surgical extension.
Relevant work from earlier we're still surfacing — not today's news.